160 related articles for article (PubMed ID: 35884417)
1. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.
Boudin L; De Nonneville A; Finetti P; Guittard G; Nunes JA; Birnbaum D; Mamessier E; Bertucci F
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884417
[TBL] [Abstract][Full Text] [Related]
2. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
3. PDL1 expression is an independent prognostic factor in localized GIST.
Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
[TBL] [Abstract][Full Text] [Related]
4. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
6. PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC).
Ghosh J; Chatterjee M; Ganguly S; Datta A; Biswas B; Mukherjee G; Agarwal S; Ahmed R; Chatterjee S; Dabkara D
Ecancermedicalscience; 2021; 15():1217. PubMed ID: 34158821
[TBL] [Abstract][Full Text] [Related]
7. Frequency of Programmed Death Receptor Ligand 1 Expression and Clinicopathological Factors Associated With Metastatic Triple-Negative Breast Cancer at a Tertiary Cancer Care Centre in South India.
Babu S; Choudhary A; Jacob L; K N L; A H R; L K R; Saldanha S; Amirtham U; C R V
Cureus; 2024 Mar; 16(3):e55880. PubMed ID: 38595897
[TBL] [Abstract][Full Text] [Related]
8. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
9. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
[TBL] [Abstract][Full Text] [Related]
10. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of PDL1 expression in pancreatic cancer.
Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
[TBL] [Abstract][Full Text] [Related]
12.
Billon E; Finetti P; Bertucci A; Niccoli P; Birnbaum D; Mamessier E; Bertucci F
Oncoimmunology; 2019; 8(11):e1655362. PubMed ID: 31646101
[TBL] [Abstract][Full Text] [Related]
13. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
Front Oncol; 2021; 11():648139. PubMed ID: 34094935
[TBL] [Abstract][Full Text] [Related]
15. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.
Bertucci F; Finetti P; Birnbaum D; Mamessier E
Oncoimmunology; 2016 Mar; 5(3):e1085148. PubMed ID: 27141340
[TBL] [Abstract][Full Text] [Related]
16. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
Bertucci F; Finetti P; Colpaert C; Mamessier E; Parizel M; Dirix L; Viens P; Birnbaum D; van Laere S
Oncotarget; 2015 May; 6(15):13506-19. PubMed ID: 25940795
[TBL] [Abstract][Full Text] [Related]
17. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
[TBL] [Abstract][Full Text] [Related]
19. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
[TBL] [Abstract][Full Text] [Related]
20. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]